NEW YORK and SYDNEY, Oct. 9, 2016 /PRNewswire/ -- EnGeneIC Ltd., a clinical stage biopharmaceutical company focused on developing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, has entered into a research collaboration with, and granted an exclusive licence option to, Takeda Pharmaceutical Company Limited (TSE: 4502).
Under the collaboration, Takeda will provide EnGeneIC with an upfront access fee and research funding to explore the feasibility of the EDV™ technology for the development of immunomodulatory candidates for oncology. EnGeneIC will conduct research and develop targeted EDVs that carry molecules which can modulate the immune system.
"The EDV stimulates the innate and potentially the adaptive immune system in its own right since it is bacterially derived. This collaboration with the first-class scientific team at Takeda is an exciting opportunity for EnGeneIC to demonstrate that our EDV platform can also deliver an immunotherapeutic payload," said Dr. Jennifer MacDiarmid, the Joint CEO of EnGeneIC.
Takeda signed agreements with EnGeneIC through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.
About EnGeneIC and the EDV™ Nanocell Technology EnGeneIC is a clinical stage biopharmaceutical company focused on developing its proprietary bacterially-derived EDV™ nanocells as a powerful nanoparticle drug, siRNA, or miRNA delivery platform designed to directly target and effectively kill tumor cells with minimal toxicity, while simultaneously stimulating the immune system's natural anti-tumor response. Intravenously injected EDV™ nanocells exit the leaky vascular system only found within tumors and attach to cancer cells via a specially designed, targeted bi-specific antibody. Once attached, the nanocell is able to enter the tumor cell and deliver a drug, siRNA, or miRNA payload at high concentrations, intracellularly. The EDV™ nanocell platform has shown promising results in early clinical studies and EnGeneIC is currently planning to commence further clinical trials in several cancer indications in Australia and the United States.
For more information, please visit www.engeneic.com.
Australia Media Contact: Felicity Moffatt
SOURCE EnGeneIC Ltd.